Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common cause of female infertility, affecting 5-10% of women of reproductive age. Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis. Therefore, we designed a present meta-analysis of randomized controlled trials to explore the effect of myo-inositol supplementation on anthropometric, metabolic, and endocrine outcomes in PCOS patients. Randomized controlled trials assessing the effectiveness of myo-inositol were identified in electronic databases like PubMed, Cochrane, Embase, MEDLINE, CINAHL, and AMED. Listed references and citations of related articles were also screened manually to identify additional studies. Research papers for which full-text copies were not available on scientific databases were procured from respective authors. Thereafter, data were extracted from included studies and analyzed using RevMan 5.3 of the Cochrane Collaboration. A total of 17 randomized controlled trials with 1083 PCOS patients were included in this meta-analysis. Among the 17 trials, 7 trials compared myo-inositol with folic acid, 8 trials compared myo-inositol with metformin, and 2 trials compared myo-inositol with oral contraceptives. No significant improvement in body mass index, waist-to-hip ratio, fasting insulin, fasting glucose, HOMA, LH, FSH, estradiol, sex hormone-binding globulin, dehydroepiandrosterone, and total testosterone levels were observed after myo-inositol treatment in PCOS patients except androstenedione and prolactin levels. Clinically significant improvement was not observed in anthropometric, metabolic, and endocrine outcomes after myo-inositol treatment in PCOS patients. However, heterogeneity between studies was high.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our findings are consistent with a recent meta-analysis by Jethaliya and colleagues (61) who examined the efficacy of MI against any comparator for anthropometric, metabolic, and endocrine outcomes in PCOS and included 17 RCTs.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [61]
In the citing paper
“Similar to our findings, they did not find any improvements in anthropometric (BMI, WHR), metabolic (fasting insulin, fasting glucose, HOMA-IR), or hormonal (luteinizing hormone, FSH, oestradiol, SHBG, DHEAS, and total testosterone levels) outcomes with the exception of androstenedione levels, which favored inositol (61).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [61]
Citations
Cites
3 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“We were unable to analyze parameters like free androgen index, glucose-insulin ratio, progesterone level, and also parameters for lipid profile, reproductive, and ovarian function in the present meta-analysis because these parameters were reported by only one or two RCTs, which were insufficient for conducting evaluat…”
Retracted- Retracted
Jamilian, H., Jamilian, M., Foroozanfard, F., Afshar Ebrahimi, F., Bahmani, F., & Asemi, Z. (2018) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2017.1383381 · Cited by 20
RetractedDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
The Epidemiology of Obesity: A Big Picture
Hruby, A., & Hu, F. B. (2015) · PharmacoEconomics · doi:10.1007/s40273-014-0243-x · Cited by 2,916
Phosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790 · cited 1×
“DCI mediates insulin-dependent androgen synthesis, whereas uptake of glucose and follicle-stimulating hormone (FSH) signaling is mediated by MI [19, 20].”
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“Along with this, long-term health consequences of PCOS are type 2 diabetes mellitus [2, 3], dyslipidemia [4], low-grade inflammation [5], endothelial dysfunction [6], and psychological distress [7, 8].”
Research works printed but not linked: 4
- Robert J, Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;9588:685–97.
- Kabel AM. Journal of pharmacological reports polycystic ovarian syndrome : insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. J Pharmacol Rep. 2016;1:1–5.
- Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35:198–206. https://doi.org/10.1080/09513590.2018.1540578. · DOI · Paper page
- Dona G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:703–10. https://doi.org/10.1530/EJE-11-0840. · DOI · Paper page
Cited by
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“…they did not find any improvements in anthropometric (BMI, WHR), metabolic (fasting insulin, fasting glucose, HOMA-IR), or hormonal (luteinizing hormone, FSH, oestradiol, SHBG, DHEAS, and total testosterone levels) outcomes with the exception of androstenedione levels, which favored inositol (61).”
BackgroundResultUnfer, V., Kandaraki, E., Pkhaladze, L., Roseff, S., Vazquez-Levin, M. H., Laganà, A. S., Chan, S. Y., Yap‐Garcia, M. I. M., Greene, N. D. E., Soulage, C. O., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100159 · Cited by 69
“…that inositol supplementation represents an effective therapeutic approach in women with PCOS, by improving metabolic and endocrine alterations, optimizing insulin and FSH signaling in the ovary, and reducing the presence of hyper-androgenism (Pkhaladze et al., 2021; Jethaliya et al., 2022).”
BackgroundFatima, K., Jamil, Z., Faheem, S., Adnan, A., Javaid, S. S., Naeem, H., Mohiuddin, N., Sajid, A., & Ochani, S. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03388-5 · Cited by 30
Skowrońska, M., Pawłowski, M., & Milewski, R. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196275 · Cited by 22
Lin, L., Chen, G., Qiao, X., Chen, Y., Deng, H., & Xu, L. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01576-0 · Cited by 22
Metadata
- Authors
- Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R.
- Corresponding author
- Patel, Roshni
- ORCID
- Patel, Roshni
- Venue
- Reproductive Sciences
- Published
- 2022-04-27
- Volume
- 29
- Issue
- 8
- Pages
- 2282-2298
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W4225100565
- Cited by
- 17
- References
- 59
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 3
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Reproductive Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- myo-inositol, polycystic ovary syndrome, insulin resistance, insulin sensitivity, anthropometric outcomes, body mass index, waist-to-hip ratio, metabolic outcomes, endocrine outcomes, androstenedione, prolactin, sex hormone-binding globulin, testosterone, metformin, folic acid, oral contraceptives, female infertility
- MeSH terms
- Female, Folic Acid, Humans, Inositol, Insulin, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. https://app.cochat.ai/papers/10.1007/s43032-022-00933-y
- The paper
- Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R. (2022). Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. Reproductive Sciences. https://doi.org/10.1007/s43032-022-00933-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.